1. Home
  2. ATXS vs ALTI Comparison

ATXS vs ALTI Comparison

Compare ATXS & ALTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ATXS
  • ALTI
  • Stock Information
  • Founded
  • ATXS 2008
  • ALTI 2020
  • Country
  • ATXS United States
  • ALTI United States
  • Employees
  • ATXS N/A
  • ALTI N/A
  • Industry
  • ATXS Biotechnology: Pharmaceutical Preparations
  • ALTI Investment Managers
  • Sector
  • ATXS Health Care
  • ALTI Finance
  • Exchange
  • ATXS Nasdaq
  • ALTI Nasdaq
  • Market Cap
  • ATXS 424.4M
  • ALTI 394.0M
  • IPO Year
  • ATXS 2015
  • ALTI N/A
  • Fundamental
  • Price
  • ATXS $7.52
  • ALTI $3.66
  • Analyst Decision
  • ATXS Buy
  • ALTI
  • Analyst Count
  • ATXS 6
  • ALTI 0
  • Target Price
  • ATXS $33.00
  • ALTI N/A
  • AVG Volume (30 Days)
  • ATXS 436.6K
  • ALTI 186.7K
  • Earning Date
  • ATXS 11-12-2025
  • ALTI 11-07-2025
  • Dividend Yield
  • ATXS N/A
  • ALTI N/A
  • EPS Growth
  • ATXS N/A
  • ALTI N/A
  • EPS
  • ATXS N/A
  • ALTI N/A
  • Revenue
  • ATXS N/A
  • ALTI $217,760,000.00
  • Revenue This Year
  • ATXS N/A
  • ALTI $19.78
  • Revenue Next Year
  • ATXS N/A
  • ALTI $7.00
  • P/E Ratio
  • ATXS N/A
  • ALTI N/A
  • Revenue Growth
  • ATXS N/A
  • ALTI N/A
  • 52 Week Low
  • ATXS $3.56
  • ALTI $2.33
  • 52 Week High
  • ATXS $12.52
  • ALTI $5.00
  • Technical
  • Relative Strength Index (RSI)
  • ATXS 55.75
  • ALTI 42.09
  • Support Level
  • ATXS $6.95
  • ALTI $3.30
  • Resistance Level
  • ATXS $7.48
  • ALTI $3.61
  • Average True Range (ATR)
  • ATXS 0.42
  • ALTI 0.19
  • MACD
  • ATXS -0.01
  • ALTI -0.01
  • Stochastic Oscillator
  • ATXS 65.35
  • ALTI 50.00

About ATXS Astria Therapeutics Inc.

Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.

About ALTI AlTi Global Inc.

AlTi Global Inc is an independent wealth and asset manager providing entrepreneurs, multi-generational families, institutions, and emerging next-generation leaders with fiduciary capabilities as well as alternative investment strategies and advisory services. The firm has business which is organized into two business segments namely: Wealth & Capital Solutions and International Real Estate segment includes providing holistic solutions for wealth management clients through comprehensive range of wealth management services, including investment management and advisory services. International Real Estate segment includes assist investors with real estate co-investments, structuring and selecting partners with a proven track record with risk adjusted return characteristics.

Share on Social Networks: